NEW YORK (GenomeWeb) – CardioDx today announced the close of a $35 million financing round.
The funds will be used to expand the commercial use of Corus CAD and to support the company's development of other genomic tests for coronary artery disease, CardioDx said. Corus CAD is a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD.
Along with CardioDx's existing investors, Alberta Investment Management participated in the round.
In July the Redwood City, Calif.-based company said in a regulatory document that it raised $21 million toward a targeted goal of $25 million. The $35 million figure includes the July financing.
CardioDx filed for an initial public offering in October 2013 but has not gone public yet.